Contact
searchSearch
HMP Global

Non-Small Cell Lung Cancer Topic Center

News
Adjuvant Immunotherapy Costs Challenge Lung Cancer Affordability
05/04/2026
Hannah Musick
Adjuvant immunotherapies may improve lung cancer outcomes, but high costs and budget impact concerns highlight the need for biomarker-guided use, value-based pricing, and phased adoption.
Adjuvant immunotherapies may improve lung cancer outcomes, but high costs and budget impact concerns highlight the need for biomarker-guided use, value-based pricing, and phased adoption.
Adjuvant immunotherapies may...
05/04/2026
First Report Managed Care
News
Delays in Early-Stage NSCLC Surgery Linked to Systemic and Equity Gaps in Patients
04/13/2026
Rebecca Amrick
Systemic and equity gaps among patients with early-stage non–small cell lung cancer (NSCLC) lead to patients experiencing delayed surgical resection beyond the recommended 8-week window from diagnosis.
Systemic and equity gaps among patients with early-stage non–small cell lung cancer (NSCLC) lead to patients experiencing delayed surgical resection beyond the recommended 8-week window from diagnosis.
Systemic and equity gaps among...
04/13/2026
First Report Managed Care
News
Amivantamab Plus Lazertinib Expands Options for Atypical EGFR NSCLC
04/07/2026
Hannah Musick
Amivantamab plus lazertinib shows promising and durable activity in patients with advanced non–small cell lung cancer (NSCLC) harboring atypical epidermal growth factor receptor (EGFR) mutations, offering a potential new treatment option for...
Amivantamab plus lazertinib shows promising and durable activity in patients with advanced non–small cell lung cancer (NSCLC) harboring atypical epidermal growth factor receptor (EGFR) mutations, offering a potential new treatment option for...
Amivantamab plus lazertinib...
04/07/2026
First Report Managed Care
NSCLC, Oncology Coverage, Oncology Access
Videos
What PALOMA-3 Signals for Coverage, Access, and Care Delivery in NSCLC
02/02/2026
Narjust Florez, MD
In this interview, Narjust Florez, MD, discusses how subcutaneous amivantamab from the PALOMA-3 study may improve patient experience, clinic workflow, and treatment adherence while highlighting ongoing unmet needs and real-world...
In this interview, Narjust Florez, MD, discusses how subcutaneous amivantamab from the PALOMA-3 study may improve patient experience, clinic workflow, and treatment adherence while highlighting ongoing unmet needs and real-world...
In this interview, Narjust...
02/02/2026
First Report Managed Care
Non-Small Cell Lung Cancer
Videos
Optimizing NSCLC Care Through Extended Dosing and Alternative Formulations
01/27/2026
Corrine Stahura, PharmD, BCOP
Corrine Stahura, PharmD, BCOP, discusses how extended dosing intervals and subcutaneous formulations in non–small cell lung cancer are improving patient convenience, reducing infusion center burden, and enhancing operational efficiency while...
Corrine Stahura, PharmD, BCOP, discusses how extended dosing intervals and subcutaneous formulations in non–small cell lung cancer are improving patient convenience, reducing infusion center burden, and enhancing operational efficiency while...
Corrine Stahura, PharmD, BCOP,...
01/27/2026
First Report Managed Care
Non-Small Cell Lung Cancer
Videos
Treatment Paradigms in NSCLC: Chemo-Based vs Non-Chemo Regimens
01/27/2026
Rajat Thawani, MD
Dr Rajat Thawani discusses how biomarker-driven strategies, emerging immunotherapies, and novel delivery approaches are rapidly redefining first-line non-small cell lung cancer (NSCLC) treatment—shifting care beyond traditional chemotherapy...
Dr Rajat Thawani discusses how biomarker-driven strategies, emerging immunotherapies, and novel delivery approaches are rapidly redefining first-line non-small cell lung cancer (NSCLC) treatment—shifting care beyond traditional chemotherapy...
Dr Rajat Thawani discusses how...
01/27/2026
First Report Managed Care
Non-Small Cell Lung Cancer
Videos
Evaluating Total Cost Considerations in Non–Small Cell Lung Cancer Care
01/27/2026
Estelamari Rodriguez, MD, MPH
As new subcutaneous and targeted therapies enter the NSCLC landscape, the true cost of care extends far beyond drug price alone. In this interview, Estelamari Rodriguez, MD, MPH, a thoracic oncologist at Sylvester Comprehensive Cancer Center,...
As new subcutaneous and targeted therapies enter the NSCLC landscape, the true cost of care extends far beyond drug price alone. In this interview, Estelamari Rodriguez, MD, MPH, a thoracic oncologist at Sylvester Comprehensive Cancer Center,...
As new subcutaneous and targeted...
01/27/2026
First Report Managed Care
News
Stage and Access Predict Outcomes in Early Onset NSCLC
11/10/2025
Juliet Gallagher
Early-onset non–small cell lung cancer (NSCLC) remains understudied. A retrospective cohort analysis published in JAMA Network Open used SEER data (2010–2021) to evaluate which demographic, clinical, and socioeconomic factors are associated...
Early-onset non–small cell lung cancer (NSCLC) remains understudied. A retrospective cohort analysis published in JAMA Network Open used SEER data (2010–2021) to evaluate which demographic, clinical, and socioeconomic factors are associated...
Early-onset non–small cell lung...
11/10/2025
First Report Managed Care
Hsu Headshot
Videos
Understanding the Changing Landscape of NSCLC in the US
07/11/2025
Melinda Hsu, MD
Dr. Melinda Hsu, thoracic oncologist and cancer survivorship director at UH Simon Cancer Center, shares insights on the evolving landscape of non–small cell lung cancer—highlighting challenges in early detection, treatment tolerability, and...
Dr. Melinda Hsu, thoracic oncologist and cancer survivorship director at UH Simon Cancer Center, shares insights on the evolving landscape of non–small cell lung cancer—highlighting challenges in early detection, treatment tolerability, and...
Dr. Melinda Hsu, thoracic...
07/11/2025
First Report Managed Care
Rodriguez Headshot
Videos
Addressing Disparities in NSCLC With Timely Biomarker Testing and Navigation Tools
07/11/2025
Estelamari Rodriguez, MD, MPH
Dr. Estelamari Rodriguez, clinical research lead for thoracic oncology at the University of Miami Sylvester Cancer Center, explores how early biomarker testing, equitable access, artificial intelligence (AI)-driven data integration, and...
Dr. Estelamari Rodriguez, clinical research lead for thoracic oncology at the University of Miami Sylvester Cancer Center, explores how early biomarker testing, equitable access, artificial intelligence (AI)-driven data integration, and...
Dr. Estelamari Rodriguez,...
07/11/2025
First Report Managed Care
Interactive Features
Poll Quiz

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use